SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...
Elevated serum cholesterol is a major heart disease risk factor. There can be a genetic link responsible for high cholesterol, but for the vast majority of us, lifestyle and diet will be the key ...
Findings of reduced risks for mortality and major CVD suggest consideration of statins in all adults with type 2 diabetes, even in those with low short-term predicted CVD risk.
The target trial emulation study suggests rigid risk thresholds aren’t needed to steer statin use in this group.
Woman's World on MSN
Which statin is right for you? Compare meds with this handy intensity chart you'll want to save for future reference
If you have high cholesterol, there's a good chance your doctor has recommended statins to get your numbers back into a ...
Statin drugs that lower cholesterol have become popular. Merck, which manufactures the statin drug, Mevacor, thinks its product is safe enough to be sold without a prescription. An advisory committee ...
For adults with T2DM, statin initiation is associated with reductions in all-cause mortality and major CVD risk.
Morning Overview on MSN
Statin pain finally explained after 30 years of mystery
For decades, statins have been the quiet workhorses of cardiology, cutting heart attack and stroke risk for millions while ...
SAN FRANCISCO, CA—Huifeng Yun, PhD, and colleagues from the University of Alabama at Birmingham, in Birmingham, AL presented data stating that low adherence to antihypertensive medication may be ...
Background: High copayments may present a barrier to medication adherence among patients with chronic conditions such as hyperlipidemia. Objective: To assess the effects of statin copayments on statin ...
A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV ...
The cholesterol-lowering medication alirocumab, a PCSK9 inhibitor, along with a statin, lowered LDL cholesterol levels more than 50% in patients after a heart transplant, compared to those taking a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results